Experience with the routine use of erythromycin for chlamydial infections in pregnancy

J. Schachter, Richard L Sweet, M. Grossman, D. Landers, M. Robbie, E. Bishop

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

In an effort to prevent perinatal acquisition of Chlamydia trachomatis, we offered treatment with erythromycin ethylsuccinate (400 mg four times a day for seven days, given at 36 weeks' gestation) to 184 pregnant women with cervical chlamydial infections. Thirty-two women refused treatment; 24 of their infants were followed and served as the controls. Therapy was discontinued by 5 of 10 women who had gastrointestinal disturbances. Forty-seven women who completed therapy refused infant follow-up; in four (9%) of these women, therapy had failed to eradicate the infection. Sixty women and 59 infants completed the entire protocol; 55 (92%) of the women had negative cultures for chlamydia at follow-up. Chlamydial infection developed in 4 (7%) of the 59 infants of treated mothers, as compared with 12 (50%) of the 24 infants of untreated mothers; this difference was significant (P<0.001). With a success rate of 92 percent (98 of 107 patients) in treating maternal infection and with a relatively low intolerance rate (3%; 5 of 152), this regimen appears to be an effective, although not ideal, therapy for chlamydial infection in pregnant women. We conclude that in settings in which the prevalence of chlamydia infection is high, a routine program of screening pregnant women for cervical C. trachomatis, followed by treatment of those infected, would be cost effective and would reduce infant morbidity.

Original languageEnglish (US)
Pages (from-to)276-279
Number of pages4
JournalNew England Journal of Medicine
Volume314
Issue number5
StatePublished - 1986

Fingerprint

Erythromycin
Pregnancy
Infection
Pregnant Women
Chlamydia trachomatis
Mothers
Therapeutics
Erythromycin Ethylsuccinate
Chlamydia Infections
Chlamydia
Morbidity
Costs and Cost Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schachter, J., Sweet, R. L., Grossman, M., Landers, D., Robbie, M., & Bishop, E. (1986). Experience with the routine use of erythromycin for chlamydial infections in pregnancy. New England Journal of Medicine, 314(5), 276-279.

Experience with the routine use of erythromycin for chlamydial infections in pregnancy. / Schachter, J.; Sweet, Richard L; Grossman, M.; Landers, D.; Robbie, M.; Bishop, E.

In: New England Journal of Medicine, Vol. 314, No. 5, 1986, p. 276-279.

Research output: Contribution to journalArticle

Schachter, J, Sweet, RL, Grossman, M, Landers, D, Robbie, M & Bishop, E 1986, 'Experience with the routine use of erythromycin for chlamydial infections in pregnancy', New England Journal of Medicine, vol. 314, no. 5, pp. 276-279.
Schachter, J. ; Sweet, Richard L ; Grossman, M. ; Landers, D. ; Robbie, M. ; Bishop, E. / Experience with the routine use of erythromycin for chlamydial infections in pregnancy. In: New England Journal of Medicine. 1986 ; Vol. 314, No. 5. pp. 276-279.
@article{e017c662b9dc4531acec96b2e1af4f68,
title = "Experience with the routine use of erythromycin for chlamydial infections in pregnancy",
abstract = "In an effort to prevent perinatal acquisition of Chlamydia trachomatis, we offered treatment with erythromycin ethylsuccinate (400 mg four times a day for seven days, given at 36 weeks' gestation) to 184 pregnant women with cervical chlamydial infections. Thirty-two women refused treatment; 24 of their infants were followed and served as the controls. Therapy was discontinued by 5 of 10 women who had gastrointestinal disturbances. Forty-seven women who completed therapy refused infant follow-up; in four (9{\%}) of these women, therapy had failed to eradicate the infection. Sixty women and 59 infants completed the entire protocol; 55 (92{\%}) of the women had negative cultures for chlamydia at follow-up. Chlamydial infection developed in 4 (7{\%}) of the 59 infants of treated mothers, as compared with 12 (50{\%}) of the 24 infants of untreated mothers; this difference was significant (P<0.001). With a success rate of 92 percent (98 of 107 patients) in treating maternal infection and with a relatively low intolerance rate (3{\%}; 5 of 152), this regimen appears to be an effective, although not ideal, therapy for chlamydial infection in pregnant women. We conclude that in settings in which the prevalence of chlamydia infection is high, a routine program of screening pregnant women for cervical C. trachomatis, followed by treatment of those infected, would be cost effective and would reduce infant morbidity.",
author = "J. Schachter and Sweet, {Richard L} and M. Grossman and D. Landers and M. Robbie and E. Bishop",
year = "1986",
language = "English (US)",
volume = "314",
pages = "276--279",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "5",

}

TY - JOUR

T1 - Experience with the routine use of erythromycin for chlamydial infections in pregnancy

AU - Schachter, J.

AU - Sweet, Richard L

AU - Grossman, M.

AU - Landers, D.

AU - Robbie, M.

AU - Bishop, E.

PY - 1986

Y1 - 1986

N2 - In an effort to prevent perinatal acquisition of Chlamydia trachomatis, we offered treatment with erythromycin ethylsuccinate (400 mg four times a day for seven days, given at 36 weeks' gestation) to 184 pregnant women with cervical chlamydial infections. Thirty-two women refused treatment; 24 of their infants were followed and served as the controls. Therapy was discontinued by 5 of 10 women who had gastrointestinal disturbances. Forty-seven women who completed therapy refused infant follow-up; in four (9%) of these women, therapy had failed to eradicate the infection. Sixty women and 59 infants completed the entire protocol; 55 (92%) of the women had negative cultures for chlamydia at follow-up. Chlamydial infection developed in 4 (7%) of the 59 infants of treated mothers, as compared with 12 (50%) of the 24 infants of untreated mothers; this difference was significant (P<0.001). With a success rate of 92 percent (98 of 107 patients) in treating maternal infection and with a relatively low intolerance rate (3%; 5 of 152), this regimen appears to be an effective, although not ideal, therapy for chlamydial infection in pregnant women. We conclude that in settings in which the prevalence of chlamydia infection is high, a routine program of screening pregnant women for cervical C. trachomatis, followed by treatment of those infected, would be cost effective and would reduce infant morbidity.

AB - In an effort to prevent perinatal acquisition of Chlamydia trachomatis, we offered treatment with erythromycin ethylsuccinate (400 mg four times a day for seven days, given at 36 weeks' gestation) to 184 pregnant women with cervical chlamydial infections. Thirty-two women refused treatment; 24 of their infants were followed and served as the controls. Therapy was discontinued by 5 of 10 women who had gastrointestinal disturbances. Forty-seven women who completed therapy refused infant follow-up; in four (9%) of these women, therapy had failed to eradicate the infection. Sixty women and 59 infants completed the entire protocol; 55 (92%) of the women had negative cultures for chlamydia at follow-up. Chlamydial infection developed in 4 (7%) of the 59 infants of treated mothers, as compared with 12 (50%) of the 24 infants of untreated mothers; this difference was significant (P<0.001). With a success rate of 92 percent (98 of 107 patients) in treating maternal infection and with a relatively low intolerance rate (3%; 5 of 152), this regimen appears to be an effective, although not ideal, therapy for chlamydial infection in pregnant women. We conclude that in settings in which the prevalence of chlamydia infection is high, a routine program of screening pregnant women for cervical C. trachomatis, followed by treatment of those infected, would be cost effective and would reduce infant morbidity.

UR - http://www.scopus.com/inward/record.url?scp=0022622753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022622753&partnerID=8YFLogxK

M3 - Article

C2 - 3510392

AN - SCOPUS:0022622753

VL - 314

SP - 276

EP - 279

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 5

ER -